A slower-than-usual year for medtech M&A in 2023 was reflected in relatively few company exits from the Top 100 annual listing of publicly traded device, diagnostics and healthtech companies by revenues.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?